Some Chemoimmunotherapy Regimens May Reactivate HBV in B-Cell NHL

Data from two phase 3 studies of patients with B-cell non-Hodgkin lymphoma (NHL) with resolved hepatitis B virus (HBV) infection found that obinutuzumab- or rituximab-containing regimens led to HBV reactivation in 8% of the patients.

However, nucleos(t)ide analog treatment (NAT) prevents progression to hepatitis in patients who experience HBV reactivation, and prophylactic NAT may be necessary only in patients at high risk for reactivation, according to the investigators of the studies (Blood